Core Viewpoint - The company reported that some patients discontinued participation in the trial due to concerns about excessive weight loss [1] Group 1 - The trial faced challenges as patient dropout rates increased [1]

Novo Undercuts Lilly’s Obesity Drug Price for Cash-Pay in US. Listen for more on Bloomberg Intelligence. https://t.co/JbINKj3ozP ...